The best indicator for GE HealthCare (GEHC)
We backtested 20 indicators across daily, weekly and hourly charts on real GE HealthCare (GEHC) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Bollinger Mean-Reversion
On the daily chart, this is the strongest risk-adjusted edge we found for GE HealthCare (GEHC) over ~3.5 years — beating buy-and-hold by 6.2% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Bollinger Mean-Reversion ✓ | Daily | 8.6% | 0.55 | -23.6% | 71.4% | 14 | 6.2% |
| 2 | Heikin-Ashi Trend | Daily | 0.5% | 0.13 | -23.6% | 43.0% | 165 | -1.8% |
| 3 | CCI ✓ | Daily | -0.1% | 0.12 | -43.0% | 56.2% | 16 | -2.4% |
| 4 | Rate of Change | Daily | -0.2% | 0.1 | -32.7% | 48.1% | 52 | -2.6% |
| 5 | WaveTrend (8/6/4) ✓ | Daily | -0.4% | 0.1 | -42.2% | 58.3% | 12 | -2.7% |
| 6 | Heikin-Ashi Trend | Weekly | -0.4% | 0.08 | -37.4% | 58.8% | 34 | -4.4% |
| 7 | Stochastic | Daily | -2.8% | -0.01 | -41.6% | 58.8% | 17 | -5.2% |
| 8 | ADX / DMI | Daily | -2.3% | -0.06 | -26.0% | 42.9% | 21 | -4.7% |
| 9 | EMA-10 Trend | Daily | -3.7% | -0.07 | -29.8% | 39.7% | 78 | -6.1% |
| 10 | Donchian Midline | Daily | -3.9% | -0.09 | -33.7% | 32.5% | 40 | -6.3% |
| 11 | Williams %R | Daily | -5.1% | -0.11 | -44.3% | 57.1% | 21 | -7.4% |
| 12 | Rate of Change | Weekly | -4.6% | -0.15 | -36.3% | 41.7% | 12 | -8.6% |
| 13 | EMA 20/50 Cross | Daily | -7.2% | -0.23 | -40.9% | 30.0% | 10 | -9.5% |
| 14 | EMA-10 Trend | Weekly | -5.0% | -0.17 | -35.2% | 52.9% | 17 | -8.9% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For GE HealthCare (GEHC), Bollinger Mean-Reversion on the daily timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.